Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INSY

INSYS Therapeutics (INSY) Stock Price, News & Analysis

INSYS Therapeutics logo

About INSYS Therapeutics Stock (NASDAQ:INSY)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.23
$65,799,000.00
52-Week Range
N/A
Volume
N/A
Average Volume
9.52 million shs
Market Capitalization
$21.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INSY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INSY Stock News Headlines

A new rule goes live in July — and the banks are quietly crushing it
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Aldeyra Therapeutics, Inc. (ALDX)
See More Headlines

INSY Stock Analysis - Frequently Asked Questions

INSYS Therapeutics, Inc. (NASDAQ:INSY) announced its quarterly earnings data on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.33. The firm's revenue for the quarter was down 68.1% on a year-over-year basis.

Shares of INSYS Therapeutics split before market open on Monday, March 31st 2014.The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Incyte (INCY) and BioMarin Pharmaceutical (BMRN).

Company Calendar

Last Earnings
5/10/2019
Today
8/07/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSY
Previous Symbol
NASDAQ:NEOL
CIK
1516479
Fax
N/A
Employees
226
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$124.51 million
Net Margins
-346.61%
Pretax Margin
N/A
Return on Equity
-1,430.37%
Return on Assets
-64.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.54
Quick Ratio
0.50

Sales & Book Value

Annual Sales
$82.08 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.58) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
74,570,000
Free Float
N/A
Market Cap
$21.71 million
Optionable
Optionable
Beta
3.21
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:INSY) was last updated on 8/7/2025 by MarketBeat.com Staff
From Our Partners